Table 2.
Studies included in this quantitative review
| Source | N(Act-Ctrl) | Active Treatment | Control |
|---|---|---|---|
| (1) Strehl et al. (2017) | 73–67 | SCP | EMG Biofeedback |
| (2) Gevensleben et al. (2009, 2010) | 59–35 | SCP and TBR | Cognitive training |
| (3) Geladé et al. (2016, 2018) | 39–37–36 | TBR | Exercise and MPH |
| (4) Steiner et al. (2014) | 34–32–36 | SMR | Cognitive training and Waitlist |
| NIMH-MTA Study: MTA (1999) | |||
| (5) MTA Combined | 145 | MPH & Behavioral | |
| (6) MTA Medication | 144 | MPH | |
| (7) MTA Behavioral | 144 | Behavioral | |
| (8) MTA Community Care | 146 | Community Care | |
| (9) Arns et al. (2012) | 21 | SMR, TBR or SCP | QEEG-informed |
| (10) Monastra et al. (2002) | 51 | TBR | TBR-preselection |
| (11) Kropotov et al. (2005) | 86 | SMR, TBR | Open Label |
| (12) iSPOT-A: Arns et al. (2018) | 336 | MPH | Open Label |
NFB Neurofeedback, MPH Methylphenidate, SMR Sensori-Motor Rhythm protocol, TBR Theta/Beta Ratio protocol, SCP Slow Cortical Potential protocol, Act Active treatment, Ctrl control condition. Studies 1–8 are RCT’s and studies 9–12 are Open-Label effectiveness studies